AAVXF:OTCMKTS
Abivax SA
139,00 USD
0,00%
(0,00) 1 D.
07-09, 09:30:01 GMT−4 · USD
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „AAVXF“ įžvalgos...
Rinkos kapitalizacija
6,88 mlrd.
Vid. kiekis
0,00
Apimtis
0,00
52 sav. aukšta
139,00 USD
52 sav. žema
71,26 USD
Beta
3,09
Neapmokėtos akcijos
87,53 mln.
Darbuotojų skaičius
98
Rinkos kapitalizacija
6,88 mlrd.
Vid. kiekis
0,00
Apimtis
0,00
52 sav. aukšta
139,00 USD
52 sav. žema
71,26 USD
Beta
3,09
Neapmokėtos akcijos
87,53 mln.
Darbuotojų skaičius
98
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
TradingView
·
prieš 45 minutes
Abivax SA Stock 12‑Month Price Target Cut to $159.06, Implies 79% Upside
Ideal Investisseur
·
prieš 22 valandas
Abivax: stock plunges 1.5% and deepens its fall to 39% in three months
MarketBeat
·
prieš 2 dienas
676,589 Shares in Abivax SA Sponsored ADR $ABVX Acquired by Two Seas Capital LP
Profilis
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Apie „Abivax SA“
Generalinis direktoriusMarc de Garidel | Hartmut J. Ehrlich
Darbuotojai98
Įkurta2013-12-04
Pagrindinė būstinė-
Sektorius-
Svetainėabivax.com